<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662090</url>
  </required_header>
  <id_info>
    <org_study_id>EWOG MDS 2006</org_study_id>
    <nct_id>NCT00662090</nct_id>
    <nct_alias>NCT00898339</nct_alias>
  </id_info>
  <brief_title>Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood</brief_title>
  <acronym>EWOG MDS 2006</acronym>
  <official_title>Prospective Non-randomized Multi-center Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to improve the accuracy of diagnosis for children and adolescents
      with MDS by a standardized review of morphology and standardized cytogenetic and molecular
      analysis.

      The primary objectives of the study are:

        -  To evaluate the frequency of the different subtypes of MDS in childhood and adolescence
           by a standardized diagnostic approach

        -  To evaluate the frequency of cytogenetic and molecular abnormalities:

      Specifically using array-CGH to evaluate the frequency of subtle chromosomal imbalances, i.e.
      gains and losses of defined chromosomal regions, and amplifications.

      Specifically using mFISH to identify unknown chromosomal aberrations, particularly subtle
      translocations involving new candidate genes, and to better define chromosomal breakpoints.

      The secondary objectives of the study are:

        -  To assess survival for children and adolescents with MDS and JMML

        -  To evaluate relapse rate, morbidity and mortality in children with MDS and JMML treated
           by HSCT
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the frequency of the different subtypes of MDS in childhood and adolescence by a standardized diagnostic approach</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the frequency of cytogenetic and molecular abnormalities</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess survival for children and adolescents with MDS and JMML</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate relapse rate, morbidity and mortality in children with MDS and JMML treated by HSCT</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      At diagnosis, prior to HSCT and at relapse material form peripheral blood and bone marrow
      will be retrieved and stored for research purposes. If there are other diagnostic bone marrow
      examinations at other time points (prior to HSCT), the material will be handled the same way.

      The following material will be retrieved:

        -  8 smears from PB

        -  8 smears from BM

        -  at least 5 ml of heparinized PB

        -  at least 5 ml of heparinized BM
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        MDS and JMML diagnosted
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent by the caretakers and whenever possible the patient's assent.

          -  Confirmed diagnosis of MDS or JMML (morphology, cytogenetics)

          -  Myeloid leukemia of Down syndrome (patients aged &gt; 6 years).

          -  Age less than 18 years

        Exclusion Criteria:

          -  Denied informed consent and/or assent by caretakers/patient.

          -  Myeloid leukemia of Down syndrome (patients &lt; 6 years).

          -  Participation in another study within the last 4 weeks (except for therapy optimizing
             studies in cancer or bone marrow failure disorders and studies in diagnostics).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>215 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte M. Niemeyer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Freiburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte M. Niemeyer, M.D.</last_name>
    <phone>49-761-270</phone>
    <phone_ext>45060</phone_ext>
    <email>charlotte.niemeyer@uniklinik-freiburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-WÃ¼rttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte M. Niemeyer, M.D.</last_name>
      <phone>49-761-270</phone>
      <phone_ext>4506</phone_ext>
      <email>charlotte.niemeyer@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Charlotte M. Niemeyer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ewog-mds.org</url>
    <description>Homepage of the EWOG-MDS-Study Group</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>Charlotte Niemeyer, MD</investigator_full_name>
    <investigator_title>Prof. Dr. Charlotte Niemeyer, MD</investigator_title>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>JMML</keyword>
  <keyword>EWOG-MDS</keyword>
  <keyword>Myelodysplastic Syndromes (MDS)</keyword>
  <keyword>Juvenile Myelomonocytic Leukemia (JMML)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

